menu

Loading...

EVGN Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

0.864

Open

0.864

VWAP

0.86

Vol

102.00

Mkt Cap

7.53M

Low

0.864

Amount

88.13

EV/EBITDA(TTM)

--

Total Shares

8.72M

EV

10.20M

EV/OCF(TTM)

--

P/S(TTM)

0.80

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Show More

Events Timeline

(ET)

2026-02-17

08:10:00

Evogene Partners with QUT to Develop Novel Cancer Drugs

2026-02-11 (ET)

2026-02-11

08:10:00

Evogene Collaborates with Systasy to Develop New Therapies

2026-02-10 (ET)

2026-02-10

08:20:00

Evogene Expands Collaboration with Google Cloud

2026-02-05 (ET)

2026-02-05

06:00:00

Evogene and Shanghai Lishan Biopharmaceuticals Sign Exclusive Licensing Agreement for BMC128

2026-02-04 (ET)

2026-02-04

08:10:00

Evogene and Shanghai Lishan Biopharmaceuticals Sign Exclusive Licensing Agreement for BMC128

2026-01-07 (ET)

2026-01-07

07:20:00

Evogene Partners with Unravel Biosciences to Develop Neurological Disease Therapy

2025-12-30 (ET)

2025-12-30

07:10:00

Evogene Appoints Dr. Olga Nissan as VP of Business Development

2025-11-11 (ET)

2025-11-11

07:05:33

Evogene's Casterra and Fantini Reveal Strategic Partnership

2025-08-22 (ET)

2025-08-22

05:52:22

Evogene announces Q2 earnings per share of 10 cents, compared to a loss of 5 cents last year.

2025-08-19 (ET)

2025-08-19

07:06:04

Evogene announces Q2 continuing operations EPS of 50 cents compared to a loss of 85 cents last year.

News

Globenewswire

13:46 PMGlobenewswire

Clean Energy Virtual Investor Conference Scheduled for March 5th

PRnewswire

02-25PRnewswire

Evogene Updates on Strategic Progress and Outlook

PRnewswire

02-19PRnewswire

Evogene Schedules Q4 and Full Year 2025 Financial Results Call

stocktwits

02-10stocktwits

Evogene Enters Warrant Inducement Agreement Amid Stock Decline

PRnewswire

02-10PRnewswire

Evogene Enters Warrant Inducement Agreement with Investor

Newsfilter

02-10Newsfilter

Evogene Enters Warrant Inducement Agreement with Investor

1 Analyst Rating

Wall Street analysts forecast EVGN stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.50

Averages

2.50

High

2.50

Current: 0.000

Low

2.50

Averages

2.50

High

2.50

Alliance Global Partners

Scott Henry

Buy

downgrade

$6

AI Analysis

2025-06-06

Reason

Alliance Global Partners

Scott Henry

Price Target

$6

AI Analysis

2025-06-06

downgrade

Buy

Reason

Alliance Global Partners analyst Scott Henry lowered the firm's price target on Evogene to $3.50 from $6 and keeps a Buy rating on the shares, citing lower forecasts and potentially higher equity dilution after the company reported Q1 earnings that featured a revenue shortfall offset by cost cuts. The Lavie Bio sale should fortify the balance sheet, although at a lower price than expected, and Casterra castor seed revenue continues to trail the firm's forecasts, the analyst noted.

Lake Street

Ben Klieve

Buy

downgrade

$5

2025-05-22

Reason

Lake Street

Ben Klieve

Price Target

$5

2025-05-22

downgrade

Buy

Reason

Lake Street analyst Ben Klieve lowered the firm's price target on Evogene to $3.50 from $5 and keeps a Buy rating on the shares. Mixed Q1 results were highlighted by an extended cash runway via a Lavie Bio asset sale and strong year-over-year growth out of Casterra, the analyst tells investors. The number of potential catalysts is declining, but a major potential event of a follow on seed order and/or commercial castor oil agreement "represent the major potential events in 2025," the analyst says. The firm maintains a Buy rating on Evogene, but adds that "our conviction has been on the decline for several quarters."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EVGN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Evogene Ltd (EVGN.O) is -0.97, compared to its 5-year average forward P/E of -1.77. For a more detailed relative valuation and DCF analysis to assess Evogene Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.77

Current PE

-0.97

Overvalued PE

-0.30

Undervalued PE

-3.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.64

Current EV/EBITDA

-1.57

Overvalued EV/EBITDA

0.11

Undervalued EV/EBITDA

-1.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

30.01

Current PS

3.53

Overvalued PS

94.04

Undervalued PS

-34.02

Financials

AI Analysis

Annual

Quarterly

Whales Holding EVGN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Evogene Ltd (EVGN) stock price today?

The current price of EVGN is 0.864 USD — it has increased 0

What is Evogene Ltd (EVGN)'s business?

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

What is the price predicton of EVGN Stock?

Wall Street analysts forecast EVGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVGN is2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Evogene Ltd (EVGN)'s revenue for the last quarter?

Evogene Ltd revenue for the last quarter amounts to 312.00K USD, decreased -82.07

What is Evogene Ltd (EVGN)'s earnings per share (EPS) for the last quarter?

Evogene Ltd. EPS for the last quarter amounts to 0.44 USD, decreased -133.59

How many employees does Evogene Ltd (EVGN). have?

Evogene Ltd (EVGN) has 117 emplpoyees as of March 03 2026.

What is Evogene Ltd (EVGN) market cap?

Today EVGN has the market capitalization of 7.53M USD.